Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for End‐Stage Liver Disease Recipients

Catherine E. Kling, James D. Perkins, Jorge D. Reyes, Martin I. Montenovo – 10 April 2018 – In this era of organ scarcity, living donor liver transplantation (LDLT) is an alternative to using deceased donors, and in Western countries, it is more often used for recipients with low Model for End‐Stage Liver Disease (MELD) scores. We sought to compare the patient survival and graft survival between recipients of liver transplantation from living donors and donation after circulatory death (DCD) donors in patients with low MELD scores.

Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin‐2 and neutrophil extracellular traps

Hongjie Li, Dechun Feng, Yan Cai, Yudong Liu, Mingjiang Xu, Xiaogang Xiang, Zhou Zhou, Qiang Xia, Mariana J. Kaplan, Xiaoni Kong, Bin Gao – 10 April 2018 – Lipocalin‐2 (LCN2), also known as neutrophil gelatinase‐associated lipocalin (NGAL), a key antibacterial protein, is highly elevated in patients with end‐stage liver disease that is often associated with bacterial infection. LCN2 is expressed at high levels in both hepatocytes and neutrophils; however, how hepatocyte‐derived and neutrophil‐derived LCN2 cooperate to combat bacterial infection remains unclear.

12 Weeks of a Ribavirin‐Free Sofosbuvir and Nonstructural Protein 5AInhibitor Regimen Is Enough to Treat Recurrence of Hepatitis CAfter Liver Transplantation

Pauline Houssel‐Debry, Audrey Coilly, Claire Fougerou‐Leurent, Caroline Jezequel, Christophe Duvoux, Victor Ledinghen, Sylvie Radenne, Nassim Kamar, Vincent Leroy, Vincent Di Martino, Louis D'Alteroche, Valérie Canva, Filomena Conti, Jerome Dumortier, Hélène Montialoux, Pascal Lebray, Danielle Botta‐Fridlund, Albert Tran, Christophe Moreno, Christine Silvain, Camille Besch, Philippe Perre, Claire Francoz, Armando Abergel, François Habersetzer, Maryline Debette‐Gratien, Carole Cagnot, Alpha Diallo, Stéphane Chevaliez, Emilie Rossignol, Aurélie Veislinger, Jean‐Charles Duclos‐Vallee, Georges‐

Pediatric cirrhotic cardiomyopathy: Impact on liver transplant outcomes

Norman Junge, Claudia Junge, Julian Schröder, Eva‐Doreen Pfister, Christoph Leiskau, Dagmar Hohmann, Philipp Beerbaum, Ulrich Baumann – 10 April 2018 – In adults, cirrhotic cardiomyopathy (CCM) has a significant incidence and impact on liver transplantation. For pediatric liver transplantation (pLT), data on liver‐induced cardiac changes are scarce, and in particular, the comparison between cirrhotic and noncirrhotic liver disease has not been investigated.

Hepatoma cell‐secreted exosomal microRNA‐103 increases vascular permeability and promotes metastasis by targeting junction proteins

Jian‐Hong Fang, Zi‐Jun Zhang, Li‐Ru Shang, Yu‐Wei Luo, Yi‐Fang Lin, Yunfei Yuan, Shi‐Mei Zhuang – 10 April 2018 – Increased vascular permeability facilitates metastasis. Emerging evidence indicates that secreted microRNAs (miRNAs) may mediate the crosstalk between cancer and stromal cells. To date, whether and how secreted miRNAs affect vascular permeability remains unclear. Based on deep sequencing and quantitative PCR, we found that higher level of serum miR‐103 was associated with higher metastasis potential of hepatocellular carcinoma (HCC).

Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosis

Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang – 7 April 2018 – Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV‐related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines.

Subscribe to